A once-daily pill version of a GLP-1 drug helped adults with obesity or overweight lose up to 11.3% more of their body weight than placebo in 36 weeks, according to the phase 2b ACCESS trial published June 5, 2026 in Nature Medicine. The drug, aleniglipron, was tested against placebo in 230 adults, and it is a small molecule rather than a peptide, so it is swallowed instead of injected.
Key takeaways
- At 36 weeks, body weight fell 8.2% more than placebo on the 45 mg dose, 9.8% more on 90 mg and 11.3% more on 120 mg.
- Stomach and bowel side effects were mostly mild to moderate and got less frequent over time. Treatment-related discontinuations were 10.4% across the drug arms.
- This was a 230-person dose-finding trial, not a trial designed to prove long-term benefit or safety.
What the study found
Researchers randomly assigned 230 adults to one of three dose groups (45, 90 or 120 mg) or to placebo, with the dose stepped up every four weeks over 36 weeks. Participants had an average body mass index of 39.5, and 54% were female.
The trial hit its main goal. Compared with placebo, the extra weight lost was 8.2% on 45 mg, 9.8% on 90 mg and 11.3% on 120 mg. For the highest dose, the true placebo-adjusted effect is very likely somewhere between 8.6% and 13.9% (95% confidence interval). There was less than a 1 in 10,000 chance that these results are coincidence at every dose (P < 0.0001).
The weight curves had not flattened by the end of the blinded period, and weight loss kept going in the open-label extension that followed.
On safety, gastrointestinal events were “generally mild to moderate and decreased in frequency over time,” according to the paper, with no cases of drug-induced liver injury. Roughly three quarters of participants finished treatment in each group, including placebo.
Robert Kushner, MD, of Northwestern Medicine and a co-author, said in a Northwestern release: “We didn’t find any concerns; no new safety signals. We found a dose that seems to be effective, and the dose escalation will be slowed down further as we go into phase III trial to increase tolerability.”
Dr. Kumar’s take
The headline number is not the news. The delivery is.
Every GLP-1 drug most people have heard of is a peptide. Peptides are fragile, so they get injected, they often need refrigeration, and they are hard and expensive to make at scale. That is a large part of why supply has been tight and prices have stayed high. Aleniglipron is a chemical, not a protein, the same category as aspirin or a blood pressure tablet. If a pill can produce this much weight loss, the manufacturing ceiling that has rationed these drugs starts to lift.
Now the limits. Two hundred thirty people over 36 weeks is a dose-finding study. It tells you which dose to carry forward, not whether the drug works or is safe over years. Phase 3 is where that gets answered.
The 10.4% discontinuation figure is the number I would watch most closely. Oral GLP-1 competitors have run into trouble on stomach tolerability, not on effectiveness, and 10.4% is respectable but not trivial for a drug people would take indefinitely. Kushner’s comment that the dose escalation will be slowed further in phase 3 is a signal that tolerability is the live problem.
Comparisons circulating online put this next to injectable semaglutide or tirzepatide. Nobody has run that head to head. Lining up percentages from separate trials with different patients and different follow-up is not a fair fight. It is a talking point, not evidence. The same caution applies to the other oral contenders, including a daily weight-loss pill that helped people lose nearly 12% of their weight.
What it means for you
Aleniglipron is not available. It is not approved, and phase 3 has not reported. Nothing here changes a treatment decision today.
If you are considering a GLP-1, the takeaway is that the pill category is moving fast and the injection is unlikely to be the only option for long. That matters if needles, refrigeration, or cost are what has kept you away.
If you are on one of these drugs now, the harder question is what happens when you stop, which is a separate and well-studied problem. I covered that in can a daily pill keep weight off after weight-loss shots?
If stomach upset is what has made a GLP-1 hard to tolerate, raise the timing with your doctor: side effects faded as this study went on, and slowing the dose increase is the standard lever.